% | $
Quotes you view appear here for quick access.


  • jwrye jwrye Jan 19, 2010 12:28 PM Flag


    The Co’s decision by not taking action to avoid delisting does not mean they are finished but serious concerns are evident. No potential products near phase 3 and the Cash Flow burn rate not good. Every one knows that, therefore something must be holding the SP above 2 or 3¢. Book value based on patents is different than real property holdings. Where are we going from here? The toilet or is a white knight going to rescue at best the LT potential or possibilities.

    October 15, 2007 “Top 10 Emerging Biotech Stocks” 3) Targeted Genetics (TGEN): Already up about 15% from my report date after CEO presented on Weds 10-Oct with expectation of confirmatory molecular testing results from the Univ. of Chicago due by "mid-October" so TGEN can apply to have clinical hold lifted by FDA on trials of its gene therapy candidate for inflammatory arthritis conditions. Look for stock to trade over $3 next week on test results and then higher after FDA releases hold & trial resumes by EOY07 (trial is still on track despite the clinical hold as long as confirmatory testing results next week match the prelim results which show no role of TGEN's gene therapy candidate in the trial death which caused clinical hold).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • See my note in one of the prior messages... I think that if they just stop spending and give the final $3.5 royalty payment to the shareholders, the stock may be worth about $0.15. If they burn through the cash the stock is not worth $0.02

      That is my $0.02 worth